Trial Profile
Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Imiquimod (Primary)
- Indications Squamous cell cancer
- Focus Adverse reactions
- 21 Jul 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
- 21 Jul 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2024.
- 06 Oct 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.